Clinical Scorecard: SARS-CoV-2 Infection Among Fully Vaccinated Individuals Diagnosed with Multiple Myeloma
At a Glance
Category
Detail
Condition
Multiple Myeloma (MM) patients with SARS-CoV-2 infection despite full COVID-19 vaccination
Key Mechanisms
Immune dysregulation from MM and anti-tumor treatments leading to suboptimal vaccine-induced humoral response
Target Population
Patients with Multiple Myeloma or Smoldering Multiple Myeloma (SMM), including those on anti-CD38 or anti-BCMA therapies
Care Setting
Hematology and oncology outpatient and inpatient settings managing MM patients
Key Highlights
MM patients have higher risk of severe COVID-19 and mortality, especially older patients, those with active disease, high risk, or renal failure.
Fully vaccinated MM patients can still develop SARS-CoV-2 infection, often with suboptimal antibody responses, particularly if on anti-CD38 or anti-BCMA treatments.
SARS-CoV-2 variants in breakthrough infections among MM patients reflected circulating strains, predominantly Delta variant during study period.
Guideline-Based Recommendations
Diagnosis
Use real-time reverse-transcriptase PCR on nasopharyngeal swabs to confirm SARS-CoV-2 infection in symptomatic or exposed MM patients.
Perform viral genotyping to identify SARS-CoV-2 variants in breakthrough infections.
Management
Vaccinate all MM patients against SARS-CoV-2 as recommended by the International Myeloma Society.
Monitor MM patients closely for COVID-19 symptoms even after full vaccination, especially those on immunosuppressive therapies.
Consider supportive treatments including antibiotics and steroids for COVID-19 pneumonia in MM patients; oxygen therapy as needed.
Monitoring & Follow-up
Assess humoral response to vaccination by quantitative anti-spike IgG antibody testing.
Monitor lymphopenia and immunoparesis as prognostic factors for vaccine response.
Follow institutional policies for SARS-CoV-2 screening before treatment cycles.
Risks
Suboptimal vaccine efficacy in MM patients due to disease-related immune dysregulation and immunosuppressive treatments.
Risk of breakthrough SARS-CoV-2 infection despite full vaccination, with variable clinical severity.
Potential for severe COVID-19 outcomes in MM patients with comorbidities such as renal failure, obesity, and diabetes.
Patient & Prescribing Data
260 fully vaccinated MM and SMM patients monitored; 5 cases of breakthrough SARS-CoV-2 infection reported.
Patients on anti-CD38-based regimens or with immunoparesis showed suboptimal antibody responses; infections occurred 21–140 days post second vaccine dose.
Clinical Best Practices
Vaccinate all MM patients against SARS-CoV-2 regardless of treatment status.
Perform regular serological monitoring to evaluate vaccine response in MM patients.
Maintain vigilance for COVID-19 symptoms and perform timely PCR testing even in fully vaccinated MM patients.
Consider individual patient risk factors (age, comorbidities, treatment type) when planning COVID-19 preventive and therapeutic strategies.
